Phase I/II radioimmunotherapy of non-Hodgkin's lymphoma with high dose 90Y-labeled humanized LL2 anti-CD-22 antibody [epratuzumab Y-90] and peripheral blood stem cell rescue

Trial Profile

Phase I/II radioimmunotherapy of non-Hodgkin's lymphoma with high dose 90Y-labeled humanized LL2 anti-CD-22 antibody [epratuzumab Y-90] and peripheral blood stem cell rescue

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2011

At a glance

  • Drugs Epratuzumab Y-90 (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma; Chronic lymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Feb 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov, last updated 28-2-2009.
    • 10 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top